NRX Pharmaceuticals (NRXP) Interest Expenses (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 9 years of Interest Expenses data on file, last reported at $233000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses changed N/A year-over-year to $233000.0 in Q1 2026; TTM through Mar 2026 was $233000.0, a 48.68% decrease from a year earlier, with the FY2025 full-year figure at $51.2 million, up 3.09% from the prior year.
• Interest Expenses for Q1 2026 stood at $233000.0, up from $189000.0 in the prior quarter.
• Over the last five years, Interest Expenses for NRXP reached as high as $2.5 million in Q4 2022 and fell as low as $46000.0 in Q2 2023.
• Historically, Interest Expenses has averaged $504818.2 across 5 years, with a median of $233000.0 in 2026.
• On a YoY basis, Interest Expenses climbed as much as 127350.0% in 2022 and fell as far as 99.15% in 2022.
• Year by year, Interest Expenses stood at $2.5 million in 2022, then sank by 96.86% to $80000.0 in 2023, then soared by 367.5% to $374000.0 in 2024, then sank by 49.47% to $189000.0 in 2025, then grew by 23.28% to $233000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $233000.0 in Q1 2026, $189000.0 in Q3 2025, and $374000.0 in Q1 2024.